COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan
Document Type
Article
Publication Date
12-1-2022
Abstract
The immunity of patients who recover from coronavirus disease 2019 (COVID-19) could be long lasting but persist at a lower level. Thus, recovered patients still need to be vaccinated to prevent reinfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or its mutated variants. Here, we report that the inactivated COVID-19 vaccine can stimulate immunity in recovered patients to maintain high levels of anti-receptor-binding domain (RBD) and anti-nucleocapsid protein (NP) antibody titers within 9 months, and high neutralizing activity against the prototype, Delta, and Omicron strains was observed. Nevertheless, the antibody response decreased over time, and the Omicron variant exhibited more pronounced resistance to neutralization than the prototype and Delta strains. Moreover, the intensity of the SARS-CoV-2-specific CD4+ T cell response was also increased in recovered patients who received COVID-19 vaccines. Overall, the repeated antigen exposure provided by inactivated COVID-19 vaccination greatly boosted both the potency and breadth of the humoral and cellular immune responses against SARS-CoV-2, effectively protecting recovered individuals from reinfection by circulating SARS-CoV-2 and its variants.
Recommended Citation
Liang, H., Nian, X., Wu, J., Liu, D., Feng, L., Lu, J., Peng, Y., Zhou, Z., Deng, T., Liu, J., Ji, D., Qiu, R., Lin, L., Zeng, Y., Xia, F., Hu, Y., Li, T., Duan, K., Li, X., Wang, Z., Zhang, Y., Zhang, H., Zhu, C., Wang, S., Wu, X., Wang, X., Li, Y., Huang, S., Mao, M., Guo, H., Yang, Y., Jia, R., Xufang, J., & Wang, X. (2022). COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan. Retrieved from https://repository.lsu.edu/pbrc_basic_science_pubs/24